PubMed Health⌕ Search

PubMed · 8438139

[Mortality due to chronic obstructive bronchopneumopathies].

Abstract

Many recent studies have drawn attention to the rise in chronic obstructive pulmonary disease (COPD) mortality. COPD is the fifth leading cause of death in developed countries. While the data in these studies do indeed suggest that there is a global rise in COPD mortality, the increase is chiefly confined to old COPD cohorts while mortality is falling in younger COPD cohorts. The trend is probably due to the beneficial effect of stabilization or decrease of the smoking habit in developed countries. Medical antismoking campaigns are starting to be successful. There are many factors predictive of survival in COPD. As a therapeutic approach, long-term oxygen therapy is the only treatment which has definitely been shown (by two well controlled studies) to radically improve survival in hypoxemic COPD patients. However, much indirect evidence suggests that bronchodilators or topical corticosteroids may favourably influence survival in these patients. Well controlled long-term studies on these treatments are urgently needed. In the meantime, COPD patients should benefit from these treatments and smoking should be actively discouraged, to alleviate the heavy burden of COPD morbidity and mortality.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J M Tschopp. 1993-02-06. [Mortality due to chronic obstructive bronchopneumopathies].. https://pubmed.ncbi.nlm.nih.gov/8438139/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Rituximab for treatment of opsoclonus-myoclonus syndrome in neuroblastoma.

Opsoclonus-myoclonus syndrome (OMS) is a rare paraneoplastic syndrome that occurs in 2%-3% of patients with neuroblastoma. The cause of this syndrome is believed to be immune mediated, but the exact mechanism still remains unclear. There is an urgent need to improve our current strategies for treating patients with OMS, as many patients have significant long-term neurologic deficits and behavior disorders with current treatment approaches. Therapies that have shown to improve symptoms in these patients have ranged from ACTH and corticosteroids, to intravenous gammaglobulin and plasmapheresis. We report our experience with Rituximab in a patient with neuroblastoma and OMS.

Adrenal Cortex Hormones↗

Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study.

Although the calcineurin inhibitors (CNI) cyclosporine (CsA) and tacrolimus are highly effective immunosuppressants, they are associated with serious side effects. There is great interest in immunosuppressive regimens that permit reduction or elimination of CNIs, while maintaining adequate immunosuppression and acceptable acute rejection rates. Patients (n = 536) receiving their first renal allograft were randomized to one of three immunosuppressant regimens: daclizumab, mycophenolate mofetil (MMF), corticosteroids (CS) and low-dose CsA (target trough levels of 50-100 ng/mL), weaned from month 4 and withdrawn by month 6; daclizumab, MMF, CS and low-dose CsA; or MMF, CS and standard-dose CsA. Mean GFR 12 months after transplantation (primary end point) was not statistically different in the CsA withdrawal and low-dose CsA groups (both 50.9 mL/min/1.73 m(2)) vs. the standard-dose CsA group (48.6 mL/min/1.73 m(2)). At 12 months, the incidence of biopsy-proven acute rejection was significantly higher in the CsA withdrawal group (38%) vs. the low- or standard-dose CsA groups (25.4% and 27.5%, respectively; p < 0.05). In summary, a regimen of continuous low-dose CsA with MMF, CS and daclizumab induction is a clinically safe and effective immunosuppressive regimen in renal transplant recipients.

Adrenal Cortex Hormones↗